OBJECTIVE: The aim of this study was to assess diagnostic values of insulin tolerance test (ITT), glucagon stimulation test (GST), and insulin like growth factor-I (IGF-I) level, to find optimal GH cut-off values for GST, and to evaluate efficiencies of patient age, gender, body-mass index (BMI), and additional pituitary hormone deficiencies (PHDs) in the diagnosis of growth hormone deficiency (GHD). STUDY DESIGN: This retrospective study involved 216 patients with a pituitary disease and 26 healthy controls. Age, gender, BMI, medical histories, and hormonal data including baseline and stimulated hormone values were evaluated. Three cut-off values for peak GH responses to stimulation tests were evaluated: (a) 3.00 µg/L on ITT, (b) 3.00 µg/L on GST, and (c) 1.07 µg/L on GST. RESULTS: According to the ITT, GST with 3.00 µg/L cut-off, and GST with 1.07 µg/L cut-off, GHD was present in 86.1, 74.5, and 54.2 % patients, respectively. Patient age, BMI, and number of PHDs, but not gender, were found to be correlated with IGF-I and peak GH concentrations. All patients with an IGF-I concentration ≤95 ng/ml or ≥3 PHD had GHD. None of the patients with adequate GH response to the GST with 1.07 µg/L cut-off, but blunted responses to ITT and GST with 3.00 µg/L cut-off, had ≥3 PHDs. 12 out of 26 (46.2 %) healthy subjects failed the GST with 3.00 µg/L cut-off, but not with 1.07 µg/L cut-off. CONCLUSIONS: Patient age, IGF-I, BMI, and number of PHDs are efficient factors associated with the diagnosis of GHD. A 4 h GST with a diagnostic GH threshold of 1.07 µg/L seems to be a good diagnostic method for GHD.
OBJECTIVE: The aim of this study was to assess diagnostic values of insulin tolerance test (ITT), glucagon stimulation test (GST), and insulin like growth factor-I (IGF-I) level, to find optimal GH cut-off values for GST, and to evaluate efficiencies of patient age, gender, body-mass index (BMI), and additional pituitary hormone deficiencies (PHDs) in the diagnosis of growth hormone deficiency (GHD). STUDY DESIGN: This retrospective study involved 216 patients with a pituitary disease and 26 healthy controls. Age, gender, BMI, medical histories, and hormonal data including baseline and stimulated hormone values were evaluated. Three cut-off values for peak GH responses to stimulation tests were evaluated: (a) 3.00 µg/L on ITT, (b) 3.00 µg/L on GST, and (c) 1.07 µg/L on GST. RESULTS: According to the ITT, GST with 3.00 µg/L cut-off, and GST with 1.07 µg/L cut-off, GHD was present in 86.1, 74.5, and 54.2 % patients, respectively. Patient age, BMI, and number of PHDs, but not gender, were found to be correlated with IGF-I and peak GH concentrations. All patients with an IGF-I concentration ≤95 ng/ml or ≥3 PHD had GHD. None of the patients with adequate GH response to the GST with 1.07 µg/L cut-off, but blunted responses to ITT and GST with 3.00 µg/L cut-off, had ≥3 PHDs. 12 out of 26 (46.2 %) healthy subjects failed the GST with 3.00 µg/L cut-off, but not with 1.07 µg/L cut-off. CONCLUSIONS:Patient age, IGF-I, BMI, and number of PHDs are efficient factors associated with the diagnosis of GHD. A 4 h GST with a diagnostic GH threshold of 1.07 µg/L seems to be a good diagnostic method for GHD.
Authors: G Aimaretti; G Corneli; P Razzore; S Bellone; C Baffoni; E Arvat; F Camanni; E Ghigo Journal: J Clin Endocrinol Metab Date: 1998-05 Impact factor: 5.958
Authors: Christian Berg; Timo Meinel; Harald Lahner; Ali Yuece; Klaus Mann; Stephan Petersenn Journal: Eur J Endocrinol Date: 2009-12-08 Impact factor: 6.664
Authors: Mark E Molitch; David R Clemmons; Saul Malozowski; George R Merriam; Mary Lee Vance Journal: J Clin Endocrinol Metab Date: 2011-06 Impact factor: 5.958
Authors: Fahrettin Kelestimur; Vera Popovic; Alfonso Leal; P Sytze Van Dam; Elena Torres; Luisa F Perez Mendez; Yona Greenman; Hans P F Koppeschaar; Carlos Dieguez; Felipe F Casanueva Journal: Clin Endocrinol (Oxf) Date: 2006-06 Impact factor: 3.478
Authors: F F Casanueva; L Villanueva; J A Cabranes; J Cabezas-Cerrato; A Fernandez-Cruz Journal: J Clin Endocrinol Metab Date: 1984-09 Impact factor: 5.958
Authors: Amir H Hamrahian; Kevin C J Yuen; Murray B Gordon; Karen J Pulaski-Liebert; James Bena; Beverly M K Biller Journal: Pituitary Date: 2016-06 Impact factor: 4.107
Authors: Ana Beatriz Winter Tavares; Ignácio Antônio Seixas-da-Silva; Diego H S Silvestre; Maria Fernanda Castelar Pinheiro; Mario Vaisman; Flávia Lucia Conceição Journal: Endocrine Date: 2017-03-11 Impact factor: 3.633
Authors: Jose M Garcia; Beverly M K Biller; Márta Korbonits; Vera Popovic; Anton Luger; Christian J Strasburger; Philippe Chanson; Ronald Swerdloff; Christina Wang; Rosa Rosanna Fleming; Fredric Cohen; Nicola Ammer; Gilbert Mueller; Nicky Kelepouris; Frank Strobl; Vlady Ostrow; Kevin C J Yuen Journal: Endocr Connect Date: 2021-01 Impact factor: 3.335